Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | +2.19% | -4.76% | -11.95% |
05-01 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
03-18 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 8
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cyclodextrin-based Products
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -21.76% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -21.76% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Charles Strattan
FOU | Founder | 78 | 08/08/90 |
Scott Fine
CEO | Chief Executive Officer | 67 | 31/01/14 |
Joshua Fine
DFI | Director of Finance/CFO | 42 | 31/12/13 |
Jeffrey Tate
COO | Chief Operating Officer | 66 | 16/08/10 |
Michael Lisjak
LAW | General Counsel | 50 | 07/07/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Scott Fine
CEO | Chief Executive Officer | 67 | 31/01/14 |
Charles Strattan
FOU | Founder | 78 | 08/08/90 |
William Shanahan
BRD | Director/Board Member | 84 | 06/06/16 |
Chairman | 58 | 31/01/14 | |
Vivien Wong
BRD | Director/Board Member | 67 | 16/08/23 |
Shawn Cross
BRD | Director/Board Member | 56 | 12-26 |
Jeffrey Tate
COO | Chief Operating Officer | 66 | 16/08/10 |
F. Ostronic
BRD | Director/Board Member | 68 | 08/04/14 |
Randall Toig
BRD | Director/Board Member | 73 | 19/03/18 |
William Conkling
BRD | Director/Board Member | 53 | 01/05/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 28,615,740 | 17,378,910 ( 60.73 %) | 0 | 60.73 % |
Company contact information
Cyclo Therapeutics, Inc.
6714 NW 16th Street Suite B
32653, Gainesville
+
http://www.cyclotherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.95% | 40.2M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- CYTH Stock
- Company Cyclo Therapeutics, Inc.